Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
2024 · ESMO Open · 16 citations
https://doi.org/10.1016/j.esmoop.2024.102386
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
66
Papers
1.5K
Citations
16
h-index
20
i10-index
Brian Morse is an academic researcher from Moffitt Cancer Center. The author has contributed to research in topics: Neuroendocrine Tumor Research Advances & Lung Cancer Research Studies & Neuroblastoma Research and Treatments. The author has an h-index of 16, co-authored 57 publications.
ORCID: 0000-0001-6366-7222Click to start Chat